Your question is Responding to Generic Competition. Take a moment with it on the right.
Talk me through your thinking if you like. When you're confident, submit your answer and I'll grade it like a real screen (7/10 or better passes).
If a key competitor launches a generic alternative to one of GSK’s primary treatments, what financial levers would you recommend we adjust?